Efficacy looks better with daraxonrasib plus chemo versus monotherapy, but toxicity looms.

Inlexzo gets the nod in BCG-unresponsive non-muscle invasive bladder cancer, but the group has bigger plans.

But first it will need to identify the optimal dose in first-line small-cell lung cancer.

So far the data, with a Car-T Legend licensed to Novartis, lag antibody approaches.

Pivotal data set the stage for slightly delayed US accelerated approval filing.

But results come from a curated dataset, with no in-trial comparator.